IL-17 inhibitor
This page covers all IL-17 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-17A, IL-17F.
Targets
Phase 2 pipeline (1)
- ALX-0061 · Ablynx, a Sanofi company · Immunology
ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.
Patent intelligence
- il 17 inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates